ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large Population of Chemotherapy Naive Patients With Advanced NSCLC Από Ogkologos - 16 Απριλίου, 2015 640 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IGNITE study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Fedratinib 23 Δεκεμβρίου, 2020 Reducing Health Care Disparities Through Cancer Clinical Trials 30 Νοεμβρίου, 2020 FDA Approves Capivasertib with Fulvestrant for Breast Cancer 23 Νοεμβρίου, 2023 EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of... 12 Οκτωβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in... Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... Reunión anual de la American Society of Clinical Oncology de 2023:...